Evidence map›Paper›PMID 28478120›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.

George B McDonald, Laura Tabellini, Barry E Storer, Paul J Martin, Richard L Lawler, Steven L Rosinski, H Gary Schoch, John A Hansen

Abstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. The level of Tim-3+CD8+ T cells can serve as a potential marker for evaluating the severity of acute graft-versus-host disease after haplo-PBSCT.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Observational
  15. Review
  16. Review
  17. Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

George B McDonaldDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
Laura TabelliniDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Barry E StorerDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Biostatistics, University of Washington School of Medicine, Seattle, Washington.
Paul J MartinDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
Richard L LawlerDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Steven L RosinskiDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
H Gary SchochDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
John A HansenDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
TRANSPLANTATION IMMUNOLOGYP01AI033484 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MARTIN, PAUL J · 1992 to 2013
$13.1M
Project 3: Gene Therapy for Correction of Blood DisordersP01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2015 to 2019
$12.9M
Biomarker Discovery in Chronic Graft-vs-Host DiseaseR01HL094260 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HANSEN, JOHN ANDREW · 2008 to 2011
$1.8M
NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NHLBI NIH HHS P01 HL122173NHLBI NIH HHS R01 HL094260NIAID NIH HHS P01 AI033484
6 · The paper itself

Abstract

We examined the hypothesis that plasma biomarkers and concomitant clinical findings after initial glucocorticoid therapy can accurately predict failure of graft-versus-host-disease (GVHD) treatment and mortality. We analyzed plasma samples and clinical data in 165 patients after 14 days of glucocorticoid therapy and used logistic regression and areas under receiver-operating characteristic curves (AUC) to evaluate associations with treatment failure and nonrelapse mortality (NRM). Initial treatment of GVHD was unsuccessful in 49 patients (30%). For predicting GVHD treatment failure, the best clinical combination (total serum bilirubin and skin GVHD stage: AUC, .70) was competitive with the best biomarker combination (T cell immunoglobulin and mucin domain 3 [TIM3] and [interleukin 1 receptor family encoded by the IL1RL1 gene, ST2]: AUC, .73). The combination of clinical features and biomarker results offered only a slight improvement (AUC, .75). For predicting NRM at 1 year, the best clinical predictor (total serum bilirubin: AUC, .81) was competitive with the best biomarker combination (TIM3 and soluble tumor necrosis factor receptor-1 [sTNFR1]: AUC, .85). The combination offered no improvement (AUC, .85). Infection was the proximate cause of death in virtually all patients. We conclude that after 14 days of glucocorticoid therapy, clinical findings (serum bilirubin, skin GVHD) and plasma biomarkers (TIM3, ST2, sTNFR1) can predict failure of GVHD treatment and NRM. These biomarkers reflect counter-regulatory mechanisms and provide insight into the pathophysiology of GVHD reactions after glucocorticoid treatment. The best predictive models, however, exhibit inadequate positive predictive values for identifying high-risk GVHD cohorts for investigational trials, as only a minority of patients with high-risk GVHD would be identified and most patients would be falsely predicted to have adverse outcomes.

Indexed as

Graft vs Host DiseaseAcute DiseaseAdolescentAdultAgedAged, 80 and overBilirubinBiomarkersChildFemaleHepatitis A Virus Cellular Receptor 2HumansInterleukin-1 Receptor-Like 1 ProteinMaleMiddle AgedPredictive Value of TestsBilirubinBiomarkersHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2IL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinPrednisoloneReceptors, Tumor Necrosis Factor, Type IAllogeneicBiomarkerCause of deathGraft-versus-host diseaseHematopoietic cell transplantationMarrow transplantationMortalityOutcomesPositive predictive valueTreatment failure

Identifiers

PMID28478120
PMCPMC5555298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.